Summary of CRS and neurologic events Summary of CRS and neurologic events
  • In ZUMA-3, 96% of CRS events (n=69/72) and 91% of neurologic events (n=48/53) resolved2
    • In the 2-year analysis, no new-onset CRS, neurological event, infections, or hypogammaglobulinemia of any grade occurred3

Most symptoms of CRS and neurologic events occurred early
and were generally manageable
using established guidance1,4


Guidance for monitoring and management of CAR T-related adverse reactions (CRS and neurologic events)1

" " " "
Ensure that 2 doses of tocilizumab are available for each patient prior to infusion. For more information on CRS and neurologic events management, please see the full Prescribing Information for TECARTUS®
" " " "
Continue to monitor patients for signs or symptoms of these adverse reactions for 4 weeks postinfusion
" " " "
Monitor patients daily for at least 14 days postinfusion at the Authorized Treatment Center for signs and symptoms of CRS and neurologic events
" " " "
Counsel patients to seek immediate medical attention should signs or symptoms of CRS or neurologic events occur at any time

In the ZUMA-3 trial5:

  • Patients with Grade >1 treatment-related CRS or neurologic events remained hospitalized until the adverse reaction resolved
  • Discharge occurred only after all treatment-related nonhematologic toxicities returned to Grade ≤1 or baseline

AEs=adverse events; ALL=acute lymphoblastic leukemia; CAR=chimeric antigen receptor; CRS=cytokine release syndrome; R/R=relapsed or refractory.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 2. Data on file. Kite Pharma, Inc; 2021. 3. Shah BD, Ghobadi A, Oluwole OO, et al. Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy, in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia in ZUMA-3. Abstract 7010. Poster presented at the American Society of Clinical Oncology Annual Meeting; June 2-6, 2022; Chicago, IL. 4. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491-502. 5. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study – supplementary appendix. Lancet. Published online June 4, 2021. doi:10.1016/S0140-6736(21)01222-8